Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 14/20 | 0.59 |
| ▸ | TLR2 | O60603 | 1/20 | 0.59 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.59 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.46 |
| ▸ | TYR | P14679 | 1/20 | 0.46 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.46 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13605931 | 0.85 | ERN1 (0.59) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL1527154 | 0.84 | ERN1 (0.69) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL851964 | 0.82 | ALDH1A1 (0.52) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL29953692 | 0.82 | ALDH1A1 (0.52) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL10088414 | 0.81 | ERN1 (0.44) | ERN1TLR2TLR1TLR6TRIM24 | |
| SCHEMBL3658867 | 0.81 | ERN1 (0.59) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL29683824 | 0.81 | ERN1 (0.59) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL28167879 | 0.80 | ERN1 (0.42) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL30989418 | 0.79 | ERN1 (0.58) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL5069879 | 0.79 | ERN1 (0.58) | ERN1TLR2TLR1TLR6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106939026-B | Preparation and application of ruthenium metal olefin metathesis catalyst | 上海克琴科技有限公司 | 2020-03-20 | — | — | CN | disclosed |
| US-7259266-B2 | Benzopyran compounds useful for treating inflammatory conditions | PHARMACIA CORPORATION (US) | 2007-08-21 | — | — | US | disclosed |
| EP-1631562-A1 | CHROMENE DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | Pharmacia Corporation (US) | 2006-03-08 | — | — | EP | disclosed |
| EP-1615905-A2 | BENZOPYRAN COMPOUNDS USEFUL FOR TREATING INFLAMMATORY CONDITIONS | Pharmacia Corporation (US) | 2006-01-18 | — | — | EP | disclosed |
| US-20050148627-A1 | Benzopyran compounds for use in the treatment and prevention of inflammation related conditions | CARTER JEFFERY (US) | 2005-07-07 | — | — | US | disclosed |
| US-20050148777-A1 | Benzopyran compounds useful for treating inflammatory conditions | CARTER JEFFERY (US) | 2005-07-07 | — | — | US | disclosed |
| WO-2004087687-A1 | CHROMENE DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | PHARMACIA CORPORATION (US) | 2004-10-14 | — | — | WO | disclosed |
| WO-2004087686-A2 | BENZOPYRAN COMPOUNDS USEFUL FOR TREATING INFLAMMATORY CONDITIONS | PHARMACIA CORPORATION (US) | 2004-10-14 | — | — | WO | disclosed |
| EP-0119294-B1 | BENZISOXAZOLE CARBOXYLIC ACIDS | ABBOTT LABORATORIES (US) | 1987-09-16 | — | — | EP | disclosed |
| US-4490384-A | DIURETICS; HYPOTENSIVE AGENTS; CARDIOVASCULAR DISORDERS | ABBOTT LABORATORIES (US) | 1984-12-25 | — | — | US | disclosed |
| EP-0119294-A1 | Benzisoxazole carboxylic acids | ABBOTT LABORATORIES (US) | 1984-09-26 | — | — | EP | disclosed |
| WO-1984003199-A1 | BENZISOXAZOLE CARBOXYLIC ACIDS | ABBOTT LAB (US) | 1984-08-30 | — | — | WO | disclosed |
| US-4456612-A | DIURETICS | ABBOTT LABORATORIES (US) | 1984-06-26 | — | — | US | disclosed |
| EP-0011839-B1 | COUMARIN DERIVATIVES, PROCESS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Kaken Pharmaceutical Co., Ltd. (JP) | 1983-02-16 | — | — | EP | disclosed |
| US-4363812-A | 3-(Tetrazol-5-yl), 4-methyl-8-alkoxy coumarins and anti-allergic compositions thereof | KAKENYAKU KAKO CO., LTD. (JP) | 1982-12-14 | — | — | US | disclosed |
| EP-0011839-A1 | Coumarin derivatives, process for preparing the same and pharmaceutical composition containing the same | Kaken Pharmaceutical Co., Ltd. (JP) | 1980-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148777-A1 | Benzopyran compounds useful for treating inflammatory conditions | PTGES2, PTGER2, PTGS2 | ERN1 2661/4885TLR2 40/4885TLR1 105/4885 |
| US-20050148627-A1 | Benzopyran compounds for use in the treatment and prevention of inflammation related conditions | PTGES2, PTGER2, PTGES | ERN1 3395/4885TLR2 28/4885TLR1 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.